The effect of single-dose propofol injection on pain and quality of life in chronic daily headache: A randomized, double-blind, controlled trial

Anesthesia and Analgesia

Volumn 109, Issue 6, 2009, Pages 1972-1980

  Simmonds, Mark K ^a   Rashiq, Saifudin ^a   Sobolev, Igor A ^a   Dick, Bruce D ^a   Gray, Daniel P ^a   Stewart, Bradley J ^a,b   Jamieson Lega, Kathryn I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Hy's Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; AMITRIPTYLINE; ASA 292; CAFERGOT; CODEINE; CYCLOBENZAPRINE; DEXTROPROPOXYPHENE; DICLOFENAC; ELETRIPTAN; FENTANYL; HYDROMORPHONE; IBUPROFEN; KETOPROFEN; KETOROLAC; MERSYNDOL; METHADONE; MIDAZOLAM; NAPROXEN; NARATRIPTAN; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PETHIDINE; PLACEBO; PROPOFOL; PSEUDOEPHEDRINE; RIZATRIPTAN; SINUFED; SUMATRIPTAN SUCCINATE; TORODOL; UNCLASSIFIED DRUG; VERAPAMIL; ZOLMITRIPTAN;

ADULT; ANESTHESIST; ARTICLE; CHRONIC DAILY HEADACHE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; FEMALE; HUMAN; INJECTION SITE PAIN; LOW DRUG DOSE; MALE; NEURALGIA; PAIN ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE DRUG DOSE; TENSION HEADACHE; THERAPY EFFECT; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORK DISABILITY;

EID: 73949131134     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181be3f86     Document Type: Article

References (36)

1. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999;39:190-196
2. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996;47:871-875
3. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2003;43:14-18
4. AstraZeneca Pharmaceuticals LP. Diprivan 1%, professional information brochure. Wilmington, DE (USA), 2001
5. Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache 2000;40: 224-230
6. Bloomstone JA. Propofol: a novel treatment for breaking migraine headache. Anesthesiology 2007;106:405-406
7. Drummond-Lewis J, Scher C. Propofol: a new treatment strategy for refractory migraine headache. Pain Med 2002;3:366-369
8. Mendes PM, Silberstein SD, Young WB, Rozen TD, Paolone MF. Intravenous propofol in the treatment of refractory headache. Headache 2002;42:638-641
9. Roffey P, Thangathurai D. Propofol in the treatment of presurgical headache and nausea. Headache 2002;42:327
10. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002;8:355-365
11. Jacobson GP, Ramadan NM, Aggarwal SK, Newman CW. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology 1994;44:837-842
12. Campo R, Brullet E, Montserrat A, Calvet X, Donoso L, Bordas JM. Efficacy of low and standard midazolam doses for gastroscopy. A randomized, double-blind study. Eur J Gastroenterol Hepatol 2000;12:187-190
13. Holroyd KA, Nash JM, Pingel JD, Cordingley GE, Jerome A. A comparison of pharmacological (amitriptyline HCL) and nonpharmacological (cognitive- behavioral) therapies for chronic tension headaches. J Consult Clin Psychol 1991;59:387-393
14. Harden RN, Weinland SR, Remble TA, Houle TT, Colio S, Steedman S, Kee WG. Medication Quantification Scale Version III: update in medication classes and revised detriment weights by survey of American Pain Society Physicians. J Pain 2005;6:364-371
15. Holyroyd KA, Stensland M, Lipchik GL, Hill KR, O'Donnell FS, Cordingley G. Psychosocial correlates and impact of chronic tension-type headaches. Headache 2000;40:3-16
16. Headache Classification Subcommittee of the International Headache Society. International Classification of Headache Disorders. Cephalalgia 2004;24 (suppl 1):S1-S151
17. Leniger T, Wiemann M, Bingmann D, Hufnagel A, Bonnet U. Different effects of GABAergic anticonvulsants on 4-aminopyridine-induced spontaneous GABAergic hyperpolarizations of hippocampal pyramidal cells-implication for their potency in migraine therapy. Cephalalgia 2000;20:533-537
18. O'Shea SM, Wong LC, Harrison NL. Propofol increases agonist efficacy at the GABA(A) receptor. Brain Res 2000;852:344-348
19. Anwar MM, Abdel-Rahman MS. Effect of propofol on perception of pain in mice: mechanism of action. Comp Biochem Physiol A Physiol 1998;129:249-253
20. Orser BA, Bertik M, Wang LY, MacDonald JF. Inhibition by propofol (2, 6 di-isopropylphenol) of the N-methy-d-aspartate subunit of glutamate receptor in cultured hippocampal neurons. Br J Pharmacol 1995;116:1761-1768
21. Jensen AG, Lindroth M, Sjolander A, Eintrei C. Propofol induces changes in the cytosolic free calcium concentration and the cytoskeletal organization of cultured human glial cells and primary embryonic rat brain cells. Anesthesiology 1994; 81:1220-1229
22. Petros AJ, Bogle RG, Pearson JD. Propofol stimulates nitric oxide release from cultured porcine aortic endothelial cells. Br J Pharmacol 1993;109:6-7
23. Srikiatkhachorn A, Suwattanasophon C, Ruangpattanatawee U, Phansuwan-Pujito P. 5-ht2a receptor activation and nitric oxide synthesis: a possible mechanism determining migraine attacks. Headache 2002;42:566-574
24. Anker-Moller E, Spangsberg N, Arendt-Nielsen L, Schultz P, Kristensen MS, Bjerring P. Subhypnotic doses of thiopentone and propofol cause analgesia to experimentally induced acute pain. Br J Anaesth 1991;66:185-188
25. Frolich MA, Price DD, Robinson ME, Shuster JJ, Theriaque DW, Heft MW. The effect of propofol on thermal pain perception. Anesth Analg 2005;100:481-486
26. Merrill AW, Barter LS, Rudolph U, Eger EI II, Antognini JF, Carstens MI, Carstens E. Propofol's effects on nociceptive behavior and spinal c-fos expression after intraplantar formalin injection in mice with a mutation in the gamma-aminobutyric acid-type(A) receptor beta3 subunit. Anesth Analg 2006; 103:478-483
27. Sun YY, Li KC, Chen J. Inhibitory effects of spinal propofol on the responses of spinal dorsal horn neurons in normal rats. Sheng Li Xue Bao 2004;56:444-450
28. Wang QY, Cao JL, Zeng YM, Dai TJ. GABAA receptor partially mediated propofol-induced hyperalgesia at superspinal level and analgesia at spinal cord level in rats. Acta Pharmacol Sin 2004;25:1619-1625
29. Wilder-Smith OH, Kolletzki M, Wilder-Smith CH. Sedation with intravenous infusions of propofol or thiopentone. Effects on pain perception. Anaesthesia 1995;50:218-222
30. Kalso E, Tramer MR, McQuay H, Moore RA. Systemic local-anaesthetic-type drugs in chronic pain: a systematic review. Eur J Pain 1998;2:3-14
31. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006;46:766-772
32. Zacny JP, Coalson D, Young C, Klafta J, Rupani G, Thapar P, Choi M, Apfelbaum JL. A dose-response study of the effects of intravenous midazolam on cold pressor-induced pain. Anesth Analg 1995;80:521-525
33. Lindner R, Sluijter ME, Schleinzer W. Pulsed radiofrequency treatment of the lumbar medial branch for facet pain: a retrospective analysis. Pain Med 2006;7:435-439
34. Cahana A, Carota A, Montadon ML, Annoni JM. The long-term effect of repeated intravenous lidocaine on central pain and possible correlation in positron emission tomography measurements. Anesth Analg 2004;98:1581-1584
35. Boutron I, Estellat C, Ravaud P. A review of blinding in randomized controlled trials found results inconsistent and questionable. J Clin Epidemiol 2005;58:1220-1226
36. Sharpe L, Ryan B, Allard S, Sensky T. Testing for the integrity of blinding in clinical trials: how valid are forced choice paradigms? Psychother Psychosom 2003;72:128-131